Skip to main content
Erschienen in: PharmacoEconomics 12/2009

01.12.2009 | Original Research Article

Willingness to Pay for a QALY Based on Community Member and Patient Preferences for Temporary Health States Associated with Herpes Zoster

verfasst von: Dr Tracy A. Lieu, G. Thomas Ray, Ismael R. Ortega-Sanchez, Ken Kleinman, Donna Rusinak

Erschienen in: PharmacoEconomics | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

Background and Objectives: A clear sense of what society is willing to pay for a QALY could enhance the usefulness of cost-effectiveness analysis as a field. Scant information exists on willingness to pay (WTP) for a QALY based on direct elicitation of preferences from community members or patients. We had the opportunity to evaluate WTP per QALY using data from a survey on temporary health outcomes related to herpes zoster. Our aims were to (i) describe how much community members are willing to pay to save a QALY based on scenarios describing temporary health states; (ii) evaluate how WTP per QALY varies based on experience with the disease being described and with demographic variables; and (iii) evaluate how the duration and intensity of pain in a scenario influences WTP per QALY.
Methods: Community members drawn from a nationally representative survey research panel (n = 478) completed an Internet-based survey using time trade-off (TTO) and WTP questions to value a series of scenarios that described herpes zoster cases of varying pain intensity (on a scale of 0–10) and duration (30 days to 1 year). Patients with shingles (n = 354) or postherpetic neuralgia (PHN; n = 120) [defined as having symptoms for 90 days or more] from two large healthcare systems completed telephone interviews with similar questions.
Mean and median WTP per QALY values were calculated by dividing the WTP amount by the discounted time traded for each scenario. Responses with a WTP value of more than zero and a TTO value of zero (which would have resulted in an undefined value) were excluded. TTO values were discounted by 3% per year. WTP per QALY means were calculated after trimming the top and bottom 2.5% of responses. Multivariate analyses were conducted using generalized linear mixed models that assumed a negative binomial distribution.
Results: Among all respondents, the WTP per QALY ranged from a median of $US7000 to $US11 000 and a trimmed mean of $US26 000 to $US45 000 (year 2005 values), depending on the scenario described. WTP per QALY values varied significantly with respondent characteristics, as well as among respondents with similar characteristics. In multivariate analyses, the mean WTP per QALY was higher among respondents who were younger, male or had higher educational or income levels. After adjusting for these demographic variables, patients who had experienced shingles gave responses with the highest WTP per QALY values. Patients who had experienced PHN gave the lowest values, and community members gave values intermediate to the shingles and PHN groups. In multivariate models that evaluated the effects of pain and duration of the hypothetical zoster scenario, lower duration was associated with higher WTP per QALY. This effect appeared to be due to people increasing the amounts of time they would be willing to trade as duration increased, without proportional increases in the amounts of money they would be willing to pay.
Conclusions: Community members and patients gave mean WTP per QALY values that varied significantly based on age, sex, socioeconomic status, experience with shingles and duration of the health state evaluated. The variability in WTP per QALY suggests that it may be difficult to define a unitary threshold of dollars per QALY for policy making based on cost-effectiveness analyses.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20 (3): 332–42PubMedCrossRef Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20 (3): 332–42PubMedCrossRef
2.
Zurück zum Zitat Buxton M. Looking for willingness-to-pay (WTP) threshold for a QALY: does it make sense? A practical view. ISPOR Connections 2007 Aug 15; 13 (4): 9–11 Buxton M. Looking for willingness-to-pay (WTP) threshold for a QALY: does it make sense? A practical view. ISPOR Connections 2007 Aug 15; 13 (4): 9–11
3.
Zurück zum Zitat Gyrd-Hansen D. Looking for willingness to pay (WTP) threshold for a QALY: does it make sense? A critical view. ISPOR Connections 2007 Aug 15; 13 (4): 5–8 Gyrd-Hansen D. Looking for willingness to pay (WTP) threshold for a QALY: does it make sense? A critical view. ISPOR Connections 2007 Aug 15; 13 (4): 5–8
4.
Zurück zum Zitat Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. N Engl J Med 2008 Feb 14; 358 (7): 661–3PubMedCrossRef Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. N Engl J Med 2008 Feb 14; 358 (7): 661–3PubMedCrossRef
5.
Zurück zum Zitat Grosse S. Assessing cost-effectiveness in healthcare: history of the $50 000 per QALY threshold. Expert Rev Pharmacoeconomics Outcomes Res 2008; 8: 2165–78CrossRef Grosse S. Assessing cost-effectiveness in healthcare: history of the $50 000 per QALY threshold. Expert Rev Pharmacoeconomics Outcomes Res 2008; 8: 2165–78CrossRef
6.
Zurück zum Zitat Neumann PJ, Sandberg EA, Bell CM, et al. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) 2000; 19 (2): 92–109CrossRef Neumann PJ, Sandberg EA, Bell CM, et al. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) 2000; 19 (2): 92–109CrossRef
7.
Zurück zum Zitat Weinstein M. How much are Americans willing to pay for a quality-adjusted life year? Med Care 2008; 46 (4): 343–5PubMedCrossRef Weinstein M. How much are Americans willing to pay for a quality-adjusted life year? Med Care 2008; 46 (4): 343–5PubMedCrossRef
8.
Zurück zum Zitat Byrne MM, O’Malley K, Suarez-Almazor ME. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis. Med Decis Making 2005 Nov-Dec; 25 (6): 655–66PubMedCrossRef Byrne MM, O’Malley K, Suarez-Almazor ME. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis. Med Decis Making 2005 Nov-Dec; 25 (6): 655–66PubMedCrossRef
9.
Zurück zum Zitat King Jr JT, Tsevat J, Lave JR, et al. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making 2005; 25 (6): 667–77PubMedCrossRef King Jr JT, Tsevat J, Lave JR, et al. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making 2005; 25 (6): 667–77PubMedCrossRef
10.
11.
Zurück zum Zitat Lieu TA, Ortega-Sanchez I, Ray GT, et al. Community and patient values for preventing herpes zoster. Pharmacoeconomics 2008; 26 (3): 235–49PubMedCrossRef Lieu TA, Ortega-Sanchez I, Ray GT, et al. Community and patient values for preventing herpes zoster. Pharmacoeconomics 2008; 26 (3): 235–49PubMedCrossRef
12.
Zurück zum Zitat International classification of diseases. 9th ed. Geneva: World Health Organization, 1977 International classification of diseases. 9th ed. Geneva: World Health Organization, 1977
13.
Zurück zum Zitat Gold M, Siegel J, Russell L, et al. Cost-effectiveness in health and medicine. New York: Oxford University, 1996 Gold M, Siegel J, Russell L, et al. Cost-effectiveness in health and medicine. New York: Oxford University, 1996
14.
Zurück zum Zitat Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman and Hall, 1993 Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman and Hall, 1993
15.
Zurück zum Zitat Baron J, Asch DA, Fagerlin A, et al. Effect of assessment method on the discrepancy between judgments of health disorders people have and do not have: a web study. Med Decis Making 2003; 23 (5): 422–34PubMedCrossRef Baron J, Asch DA, Fagerlin A, et al. Effect of assessment method on the discrepancy between judgments of health disorders people have and do not have: a web study. Med Decis Making 2003; 23 (5): 422–34PubMedCrossRef
16.
Zurück zum Zitat Ubel PA, Loewenstein G, Jepson C. Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Qual Life Res 2003; 12 (6): 599–607PubMedCrossRef Ubel PA, Loewenstein G, Jepson C. Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Qual Life Res 2003; 12 (6): 599–607PubMedCrossRef
17.
Zurück zum Zitat Van Houtven G, Powers J, Jessup A, et al. Valuing avoided morbidity using meta-regression analysis: what can health status measures and QALYs tell us about WTP? Health Econ 2006 Aug; 15 (8): 775–95PubMedCrossRef Van Houtven G, Powers J, Jessup A, et al. Valuing avoided morbidity using meta-regression analysis: what can health status measures and QALYs tell us about WTP? Health Econ 2006 Aug; 15 (8): 775–95PubMedCrossRef
18.
Zurück zum Zitat Messonnier M, Zhou F. Review of economic studies of varicella zoster vaccine [oral presentation]. Advisory Committee on Immunization Practices (ACIP) Meeting; 2006 Oct 25; Atlanta (GA) Messonnier M, Zhou F. Review of economic studies of varicella zoster vaccine [oral presentation]. Advisory Committee on Immunization Practices (ACIP) Meeting; 2006 Oct 25; Atlanta (GA)
19.
Zurück zum Zitat Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006 Sep 5; 145 (5): 317–25PubMed Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006 Sep 5; 145 (5): 317–25PubMed
20.
Zurück zum Zitat Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007 May 15; 44 (10): 1280–8PubMedCrossRef Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007 May 15; 44 (10): 1280–8PubMedCrossRef
21.
Zurück zum Zitat Pellissier J. Evaluation of zoster vaccine cost-effectiveness [oral presentation]. Advisory Committee of Immunization Practices (ACIP) Meeting; 2006 Jun 30; Atlanta (GA) Pellissier J. Evaluation of zoster vaccine cost-effectiveness [oral presentation]. Advisory Committee of Immunization Practices (ACIP) Meeting; 2006 Jun 30; Atlanta (GA)
22.
Zurück zum Zitat Ortega-Sanchez IR. Projected cost-effectiveness of vaccinating US elderly to prevent shingles [oral presentation]. Advisory Committee for Immunization Practices (ACIP) Meeting; 2006 Jun 30; Atlanta (GA) Ortega-Sanchez IR. Projected cost-effectiveness of vaccinating US elderly to prevent shingles [oral presentation]. Advisory Committee for Immunization Practices (ACIP) Meeting; 2006 Jun 30; Atlanta (GA)
23.
Zurück zum Zitat Pellissier JM, Brisson M, Levin MJ. Evaluation of the costeffectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007 Nov 28; 25 (49): 8326–37PubMedCrossRef Pellissier JM, Brisson M, Levin MJ. Evaluation of the costeffectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007 Nov 28; 25 (49): 8326–37PubMedCrossRef
24.
Zurück zum Zitat Ho AMH, Coplan P, Lee A, et al. Cost-effectiveness of varicella zoster vaccination in older adults [abstract]. Can J Anethesia 2006; 53 Suppl. 1: 26394CrossRef Ho AMH, Coplan P, Lee A, et al. Cost-effectiveness of varicella zoster vaccination in older adults [abstract]. Can J Anethesia 2006; 53 Suppl. 1: 26394CrossRef
25.
Zurück zum Zitat Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008 Jun 6; 57 (RR-5): 1–30; quiz CE2-4PubMed Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008 Jun 6; 57 (RR-5): 1–30; quiz CE2-4PubMed
26.
Zurück zum Zitat Braithwaite RS, Meltzer DO, King Jr JT, et al. What does the value of modern medicine say about the $50 000 per qualityadjusted life-year decision rule? Med Care 2008; 46 (4): 349–56PubMedCrossRef Braithwaite RS, Meltzer DO, King Jr JT, et al. What does the value of modern medicine say about the $50 000 per qualityadjusted life-year decision rule? Med Care 2008; 46 (4): 349–56PubMedCrossRef
27.
Zurück zum Zitat Gyrd-Hansen D. Willingness to pay for a QALY: theoretical and methodological issues. Pharmacoeconomics 2005; 23 (5): 423–32PubMedCrossRef Gyrd-Hansen D. Willingness to pay for a QALY: theoretical and methodological issues. Pharmacoeconomics 2005; 23 (5): 423–32PubMedCrossRef
28.
Zurück zum Zitat Smith RD, Richardson J. Can we estimate the ‘social’ value of a QALY? Four core issues to resolve. Health Policy 2005 Sep 28; 74 (1): 77–84PubMedCrossRef Smith RD, Richardson J. Can we estimate the ‘social’ value of a QALY? Four core issues to resolve. Health Policy 2005 Sep 28; 74 (1): 77–84PubMedCrossRef
29.
Zurück zum Zitat Hammitt J, Haninger K. Willingness to pay for food safety: sensitivity to duration and severity of illness. Amer J Agr Econ 2007; 89 (5): 1170–5CrossRef Hammitt J, Haninger K. Willingness to pay for food safety: sensitivity to duration and severity of illness. Amer J Agr Econ 2007; 89 (5): 1170–5CrossRef
30.
Zurück zum Zitat Hammitt J, Graham JD. Willingness to pay for health protection: inadequate sensitivity for probability? J Risk Uncertainty 1999; 18 (1): 33–62CrossRef Hammitt J, Graham JD. Willingness to pay for health protection: inadequate sensitivity for probability? J Risk Uncertainty 1999; 18 (1): 33–62CrossRef
31.
Zurück zum Zitat Oliver A, Sorenson C. Importance of preference reversals in the valuation of health and healthcare. Expert Rev Pharmacoeconomics Outcomes Res 2008; 8 (2): 95–9CrossRef Oliver A, Sorenson C. Importance of preference reversals in the valuation of health and healthcare. Expert Rev Pharmacoeconomics Outcomes Res 2008; 8 (2): 95–9CrossRef
32.
Zurück zum Zitat Krosnick J, LinChiat C. A comparison of the random digit dialing telephone survey methodology as implemented by Knowledge Networks and Harris Interactive [presentation]. Conference of the American Association for Public Opinion Research; 2001 May 17-20; Montreal (QC) Krosnick J, LinChiat C. A comparison of the random digit dialing telephone survey methodology as implemented by Knowledge Networks and Harris Interactive [presentation]. Conference of the American Association for Public Opinion Research; 2001 May 17-20; Montreal (QC)
33.
Zurück zum Zitat Lenert LA. The reliability and internal consistency of an Internet-capable computer program formeasuring utilities. Qual Life Res 2000; 9 (7): 811–7PubMedCrossRef Lenert LA. The reliability and internal consistency of an Internet-capable computer program formeasuring utilities. Qual Life Res 2000; 9 (7): 811–7PubMedCrossRef
Metadaten
Titel
Willingness to Pay for a QALY Based on Community Member and Patient Preferences for Temporary Health States Associated with Herpes Zoster
verfasst von
Dr Tracy A. Lieu
G. Thomas Ray
Ismael R. Ortega-Sanchez
Ken Kleinman
Donna Rusinak
Publikationsdatum
01.12.2009
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 12/2009
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/11314000-000000000-00000

Weitere Artikel der Ausgabe 12/2009

PharmacoEconomics 12/2009 Zur Ausgabe

Current Opinion

Weighting Must Wait

Acknowledgments

Acknowlegement